

# Theodoros Kassimatis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5406524/publications.pdf>

Version: 2024-02-01

38  
papers

500  
citations

759233

12  
h-index

713466

21  
g-index

38  
all docs

38  
docs citations

38  
times ranked

943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney. <i>American Journal of Transplantation</i> , 2021, 21, 1012-1026.	4.7	21
2	COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity. <i>Transplantation Proceedings</i> , 2021, 53, 1160-1168.	0.6	9
3	The implications of donor-recipient size mismatch in renal transplantation. <i>Journal of Nephrology</i> , 2021, 34, 2037-2051.	2.0	2
4	UK renal transplant outcomes in low and high BMI recipients: the need for a national policy. <i>Journal of Nephrology</i> , 2020, 33, 371-381.	2.0	19
5	Hypoperfusion warm ischaemia time in renal transplants from donors after circulatory death. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1628-1634.	0.7	8
6	Duration of delayed graft function and outcomes after kidney transplantation from controlled donation after circulatory death donors: a retrospective study. <i>Transplant International</i> , 2019, 32, 635-645.	1.6	9
7	Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples. <i>EBioMedicine</i> , 2019, 41, 571-583.	6.1	28
8	Chronic histological changes in deceased donor kidneys at implantation do not predict graft survival: a single-centre retrospective analysis. <i>Transplant International</i> , 2019, 32, 523-534.	1.6	9
9	Outcomes in Third and Fourth Kidney Transplants Based on the Type of Donor. <i>Transplantation</i> , 2019, 103, 1494-1503.	1.0	14
10	A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 255.	1.6	67
11	Successful medical treatment of emphysematous pyelonephritis in chronic hemodialysis. <i>Hemodialysis International</i> , 2015, 19, E54-8.	0.9	4
12	Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: a meta-analysis. <i>Transplant International</i> , 2015, 28, 330-340.	1.6	5
13	Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation. <i>Renal Failure</i> , 2014, 36, 1310-1316.	2.1	4
14	Statins in chronic kidney disease and kidney transplantation. <i>Pharmacological Research</i> , 2014, 88, 62-73.	7.1	22
15	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0
16	Long-term safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery stenosis. <i>International Urology and Nephrology</i> , 2012, 44, 1451-1459.	1.4	9
17	Dyslipidemia, statins, and CKD patients' outcomes – review of the evidence in the post-sharp era. <i>Journal of Nephrology</i> , 2012, 25, 460-472.	2.0	16
18	Statins and prostate cancer: Molecular and clinical aspects. <i>European Journal of Cancer</i> , 2011, 47, 819-830.	2.8	64

#	ARTICLE	IF	CITATIONS
19	Paricalcitol for reduction of albuminuria in diabetes. <i>Lancet</i> , The, 2011, 377, 635.	13.7	2
20	Impaired desensitization of a human polymorphic $\beta$ -adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. <i>Cell Communication and Signaling</i> , 2011, 9, 5.	6.5	32
21	Implications of the AURORA and JUPITER results. <i>Nature Reviews Nephrology</i> , 2010, 6, 636-637.	9.6	1
22	Transcription Factor Sp1 Expression Is Upregulated in Human Glomerulonephritis: Correlation with pSmad2/3 and p300 Expression and Renal Injury. <i>Renal Failure</i> , 2010, 32, 243-253.	2.1	13
23	New Hope for Chronic Kidney Disease Patients After the JUPITER Trial. <i>Journal of the American College of Cardiology</i> , 2010, 56, 529.	2.8	2
24	Anaemia, microcytosis and sirolimus--is iron the missing link?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1667-1675.	0.7	44
25	Rosuvastatin in Patients Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2009, 361, 93-95.	27.0	6
26	Bilirubin as a predictor of albuminuria and atherosclerosis in type 2 diabetic patients: misleading data. <i>Kidney International</i> , 2009, 75, 862.	5.2	2
27	The role of statins in chronic kidney disease (CKD): Friend or foe?. , 2009, 122, 312-323.		20
28	Statins in Patients With Chronic Kidney Disease: A Double-Edged Sword?. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1679.	2.8	2
29	Fatal arteriovenous graft infection in a diabetic haemodialysis patient. <i>Emergency Medicine Journal</i> , 2008, 25, 240-240.	1.0	0
30	Prescription of Vitamin Supplementation May Not Always Be Harmless. <i>Gerontology</i> , 2008, 54, 69-70.	2.8	0
31	Letter to the Editor: "Acute Renal Failure and Hypercalcaemia: Sarcoidosis May Be the Culprit". <i>Renal Failure</i> , 2007, 29, 111-112.	2.1	1
32	A Fatal Case of Paraquat Poisoning Following Minimal Dermal Exposure. <i>Renal Failure</i> , 2007, 29, 375-377.	2.1	36
33	Chronic Exposure of Human Glomerular Epithelial Cells to High Glucose Concentration Results in Modulation of High-Affinity Glucose Transporters Expression. <i>Renal Failure</i> , 2007, 29, 353-358.	2.1	17
34	Images in Dialysis Series Editors: Ursula C. Brewster and Mark A. Perazella: Facial and Left Arm Swelling in a Hemodialysis Patient. <i>Seminars in Dialysis</i> , 2007, 20, 269-270.	1.3	0
35	Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. <i>Journal of Cellular and Molecular Medicine</i> , 2006, 10, 838-851.	3.6	1
36	Images in Dialysis: Recurrent Flushing in a Hemodialysis Patient. <i>Seminars in Dialysis</i> , 2006, 19, 558-559.	1.3	3

#	ARTICLE	IF	CITATIONS
37	The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT) Tj ETQq1 1 0.784314 5gBT /Over	0.7	5
38	Individualization of theophylline infusion rate on the basis of a nonlinear compartmental pharmacokinetic model. European Journal of Drug Metabolism and Pharmacokinetics, 1997, 22, 265-276.	1.6	3